sotatercept-csrk (Winrevair)

From Aaushi
Jump to navigation Jump to search

Indications

Dosage

  • 0.3-0.7 mg/kg of body weight every 3 weeks SQ

Injection: 45 mg, 60 mg

Adverse effects

Mechanism of action

More general terms

References

  1. 1.0 1.1 Humbert M, McLaughlin V, Gibbs JSR et al Sotatercept for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med 2021; 384:1204-1215. April 1. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33789009 https://www.nejm.org/doi/full/10.1056/NEJMoa2024277
  2. Lou N Sotatercept's FDA Approval a New Chapter for Pulmonary Arterial Hypertension. Biologic should arrive on pharmacy shelves before May. MedPage Today March 27, 2024 https://www.medpagetoday.com/cardiology/hypertension/109372
  3. HIGHLIGHTS OF PRESCRIBING INFORMATION Winrevair<TM> sotatercept-csrk for injection, for subcutaneous use https://www.merck.com/product/usa/pi_circulars/w/winrevair/winrevair_pi.pdf